Medidata Solutions, Inc. (MDSO) Given Consensus Recommendation of “Buy” by Analysts
Medidata Solutions, Inc. (NASDAQ:MDSO) has been assigned an average rating of “Buy” from the fifteen brokerages that are covering the company, MarketBeat reports. Three analysts have rated the stock with a hold rating and twelve have issued a buy rating on the company. The average twelve-month price target among brokerages that have updated their coverage on the stock in the last year is $78.36.
Several equities analysts recently issued reports on MDSO shares. Piper Jaffray Companies upped their price objective on shares of Medidata Solutions from $60.00 to $72.00 and gave the company an “overweight” rating in a research note on Tuesday, April 11th. Zacks Investment Research downgraded shares of Medidata Solutions from a “buy” rating to a “hold” rating in a research note on Thursday, April 13th. Needham & Company LLC reissued a “buy” rating and set a $65.00 price objective on shares of Medidata Solutions in a research note on Wednesday, April 19th. Jefferies Group LLC raised shares of Medidata Solutions from an “underperform” rating to a “hold” rating and set a $46.00 price target for the company in a research report on Friday, April 28th. Finally, Morgan Stanley upped their price target on shares of Medidata Solutions from $63.00 to $74.00 and gave the stock an “overweight” rating in a research report on Friday, April 28th.
In other news, EVP Michael I. Otner sold 7,500 shares of the firm’s stock in a transaction dated Monday, May 1st. The shares were sold at an average price of $66.39, for a total value of $497,925.00. Following the transaction, the executive vice president now directly owns 78,419 shares in the company, valued at approximately $5,206,237.41. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Robert Taylor sold 5,639 shares of the firm’s stock in a transaction dated Monday, June 5th. The stock was sold at an average price of $73.46, for a total transaction of $414,240.94. Following the completion of the transaction, the director now owns 54,372 shares in the company, valued at $3,994,167.12. The disclosure for this sale can be found here. Insiders have sold a total of 18,139 shares of company stock worth $1,259,466 over the last quarter. 5.80% of the stock is currently owned by insiders.
Several hedge funds have recently added to or reduced their stakes in MDSO. Brown Capital Management LLC boosted its stake in Medidata Solutions by 0.6% in the first quarter. Brown Capital Management LLC now owns 5,921,818 shares of the company’s stock worth $341,630,000 after buying an additional 33,042 shares during the period. Vanguard Group Inc. boosted its stake in Medidata Solutions by 5.1% in the first quarter. Vanguard Group Inc. now owns 4,874,974 shares of the company’s stock worth $281,237,000 after buying an additional 235,190 shares during the period. Clearbridge Investments LLC boosted its stake in Medidata Solutions by 61.4% in the first quarter. Clearbridge Investments LLC now owns 2,449,038 shares of the company’s stock worth $141,285,000 after buying an additional 931,729 shares during the period. Champlain Investment Partners LLC boosted its stake in Medidata Solutions by 11.5% in the first quarter. Champlain Investment Partners LLC now owns 1,653,230 shares of the company’s stock worth $95,375,000 after buying an additional 169,870 shares during the period. Finally, State Street Corp boosted its stake in Medidata Solutions by 17.1% in the first quarter. State Street Corp now owns 1,432,120 shares of the company’s stock worth $82,615,000 after buying an additional 209,074 shares during the period.
Shares of Medidata Solutions (NASDAQ MDSO) traded down 1.32% during mid-day trading on Friday, hitting $74.78. 525,096 shares of the stock were exchanged. The company has a 50-day moving average of $77.53 and a 200 day moving average of $63.59. Medidata Solutions has a one year low of $46.10 and a one year high of $85.92. The stock has a market cap of $4.21 billion, a PE ratio of 126.96 and a beta of 1.81.
Medidata Solutions (NASDAQ:MDSO) last announced its quarterly earnings data on Tuesday, July 18th. The company reported $0.31 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.28 by $0.03. The business had revenue of $137.41 million for the quarter, compared to the consensus estimate of $134.28 million. Medidata Solutions had a net margin of 7.07% and a return on equity of 11.14%. The company’s quarterly revenue was up 19.9% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.24 earnings per share. On average, equities analysts predict that Medidata Solutions will post $1.28 earnings per share for the current year.
COPYRIGHT VIOLATION WARNING: “Medidata Solutions, Inc. (MDSO) Given Consensus Recommendation of “Buy” by Analysts” was first posted by American Banking News and is owned by of American Banking News. If you are accessing this news story on another site, it was illegally copied and republished in violation of U.S. & international copyright & trademark legislation. The correct version of this news story can be read at https://www.americanbankingnews.com/2017/07/21/medidata-solutions-inc-mdso-given-consensus-recommendation-of-buy-by-analysts.html.
About Medidata Solutions
Medidata Solutions Inc (Medidata) is a provider of cloud-based solutions for life sciences. The Company provides cloud-based solutions for clinical research in life sciences, offering platform technology that focuses on the clinical development. The Company’s plan study addresses three areas to ensure optimal study design, grant development and negotiation, and investigator payments.
Receive News & Ratings for Medidata Solutions Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medidata Solutions Inc. and related companies with MarketBeat.com's FREE daily email newsletter.